RCE1 Antibody

What is RCE1 and why is it important in cellular research?

RCE1 (Ras Converting Enzyme 1) is an integral membrane endoprotease localized to the endoplasmic reticulum that plays a critical role in the post-translational modification pathway of CAAX proteins, including Ras. The enzyme mediates the cleavage of the carboxyl-terminal CAAX motif following prenylation, a step essential for proper membrane localization of these signaling proteins .

RCE1's significance in research stems from its fundamental role in Ras processing, which has implications for multiple cellular pathways and disease states. Studies have demonstrated that RCE1 deficiency impacts cell growth and can modify Ras-induced transformation, making it a potential therapeutic target for cancer research . Additionally, RCE1 is involved in pathways relevant to infectious diseases caused by parasites such as Plasmodium sp. and Trypanosoma brucei, broadening its research significance beyond oncology .

What structural features characterize RCE1 across species?

RCE1 orthologs demonstrate considerable variation in primary sequence identity (9-63%) and size (30-37 kDa) across species. Despite this variability, all RCE1 orthologs share several key characteristics:

• All are predicted to be multi-span membrane proteins

• Contains several conserved amino acids proposed as catalytic residues, specifically:

  • Two adjacent glutamates (E140, E141 in M. maripaludis)

  • Two separate histidines (H173, H227)

  • A conserved arginine (R145) often positioned four residues away from the glutamate pair

  • An aromatic residue (Phe or Tyr) frequently four residues from the first histidine

  • An asparagine/aspartate near the second histidine

The crystal structure of RCE1 homolog from Methanococcus maripaludis reveals 8 transmembrane α-helices with a conical cavity at its core that houses the catalytic site. This cavity opens to the cytosol and contains the conserved residues mentioned above . Topology studies in different species have yielded some contradictory results regarding the orientation of N- and C-termini, highlighting the complexity of this enzyme's structure.

What are the optimal applications for RCE1 antibodies in research protocols?

Based on validated applications, RCE1 antibodies are most effectively employed in the following research techniques:

• Western Blotting (WB): Primary application for detecting RCE1 protein expression levels in cell and tissue lysates

• Immunohistochemistry (IHC): Both standard and paraffin-embedded section protocols show reliable results for tissue localization studies

• Immunofluorescence (ICC-IF): Effective for subcellular localization studies, particularly for examining ER membrane association

• FACS analysis: Some antibodies have been validated for flow cytometry applications to analyze RCE1 expression in cell populations

When selecting an RCE1 antibody, researchers should consider the specific epitope recognition (e.g., N-terminal vs. internal domains) and cross-species reactivity. For instance, antibodies targeting the amino acid region 155-204 show broad cross-reactivity across multiple species including human, mouse, rat, and xenopus with 100% homology, while maintaining 92% reactivity with goat and zebrafish proteins .

How does RCE1 function in the Ras processing pathway?

RCE1 functions as part of a three-step post-translational modification sequence for CAAX proteins like Ras:

• Prenylation: Addition of either a farnesyl or geranylgeranyl isoprenoid to the cysteine residue of the CAAX motif by farnesyltransferase or geranylgeranyltransferase

• Endoproteolytic cleavage: RCE1-mediated removal of the -AAX tripeptide from the C-terminus

• Methylation: Carboxyl-terminal isoprenylcysteine is methylated by isoprenylcysteine carboxyl methyltransferase (Icmt)

This processing pathway is critical for proper membrane association of Ras proteins. Studies using Rce1-deficient cells have demonstrated that absence of RCE1 impairs but does not completely eliminate membrane association of Ras proteins, suggesting that RCE1-mediated processing enhances but is not absolutely required for membrane targeting . The endoproteolytic activity of RCE1 appears to be specific for prenylated substrates, with the identity of the a₂ amino acid residue in the Ca₁a₂X sequence being particularly important for substrate recognition .

What experimental systems exist for studying RCE1 function?

Researchers have developed several experimental systems to investigate RCE1 function:

• Conditional gene knockout models: Mouse models with conditional Rce1 alleles (Rce1ᶠˡᵒˣ) allow controlled study of RCE1 deficiency

• Cell-based assays: Comparative studies using Rce1⁻/⁻ and wild-type cells to assess effects on cell growth and transformation

• In vitro enzyme assays: Systems for measuring RCE1 enzymatic activity using reporter substrates

• Inhibitor studies: Experimental setups to evaluate the effects of potential RCE1 inhibitors, such as farnesyltransferase inhibitors (e.g., SCH66336)

• Structural biology approaches: Crystallography studies to elucidate the three-dimensional structure, as has been done with archaeal homologs

Researchers have also developed "competitive fitness" experiments where Rce1-expressing and Rce1-deficient cells are grown together and their relative growth is assessed over multiple passages using techniques such as Southern blotting .

What methodological considerations are important when validating RCE1 antibodies?

When validating RCE1 antibodies for research applications, several critical methodological considerations should be addressed:

• Epitope specificity verification: Given RCE1's multiple isoforms, confirm antibody specificity through:

  • Western blotting against recombinant RCE1 variants

  • Testing in samples from Rce1-knockout models as negative controls

  • Peptide competition assays using the immunizing peptide

• Cross-reactivity assessment: Systematically test against closely related proteases, particularly those with similar catalytic domains. BLAST analysis suggests high conservation across species, with antibodies raised against human RCE1 showing 100% sequence identity with multiple species and 92% with others like goat and zebrafish .

• Subcellular localization validation: As RCE1 is an ER membrane protein, validation should include colocalization studies with established ER markers to confirm proper detection of physiological localization.

• Protocol optimization for membrane proteins: Standard antibody protocols often require modification for optimal detection of multi-span membrane proteins like RCE1:

  • For Western blotting: Sample preparation should avoid boiling when possible, use mild detergents like 0.1% SDS, and include reducing agents

  • For IHC/IF: Extended antigen retrieval methods and membrane permeabilization steps are typically required

How can researchers distinguish between RCE1 isoforms using antibody techniques?

Distinguishing between RCE1 isoforms (particularly Iso1 and Iso2 in mammals) requires strategic antibody selection and experimental design:

• Isoform-specific antibodies: Select antibodies targeting regions with sequence divergence between isoforms. For human RCE1, the mammalian splice variants differ primarily in their N-terminal regions .

• Immunoblotting technique modifications:

  • Use gradient gels (10-20%) to achieve better separation of closely sized isoforms

  • Extended running times at lower voltage (60-80V) improves band resolution

  • Silver staining or highly sensitive chemiluminescent substrates may be required for detecting low-abundance isoforms

• Combined immunoprecipitation strategy:

  • First immunoprecipitate with a pan-RCE1 antibody

  • Then perform Western blotting with isoform-specific antibodies

• Verification with recombinant controls: Include purified recombinant proteins of each isoform as positive controls to establish exact molecular weight markers

• Complementary RNA analysis: Validate protein findings with RT-PCR using isoform-specific primers to correlate protein detection with transcript expression

Research has shown that USP17 (a deubiquitinating enzyme) differentially regulates RCE1 isoforms, specifically affecting Iso2 protein levels while Iso1 remains unaffected, providing a potential biological verification system for isoform-specific detection .

What are effective experimental approaches for studying RCE1 inhibitors in cancer models?

Developing experimental approaches for studying RCE1 inhibitors requires multifaceted strategies:

• Cell-based screening systems:

  • Engineer reporter cell lines expressing fluorescently-tagged CAAX proteins

  • Measure membrane localization changes upon inhibitor treatment

  • Implement high-content imaging platforms for quantitative analysis

• Biochemical assay cascade:

  • Initial screening with in vitro RCE1 enzyme assays using fluorogenic substrates

  • Secondary cellular target engagement assays

  • Tertiary assays measuring effects on downstream signaling pathways

• Genetic validation models:

  • Utilize conditional Rce1 knockout systems to compare inhibitor effects with genetic ablation

  • "Competitive fitness" experiments comparing growth of inhibitor-treated cells against untreated controls

  • Engineer inhibitor-resistant RCE1 mutants as negative controls

• Cancer-specific evaluation:

  • Test compounds in cell lines with various Ras mutation statuses (KRAS, NRAS, HRAS)

  • Evaluate effects on Ras membrane association, activation state, and downstream signaling

  • Measure inhibitory effects on cell proliferation, survival, and transformation phenotypes

• In vivo evaluation:

  • Employ xenograft models derived from Ras-dependent tumors

  • Administer inhibitors and measure effects on tumor growth

  • Analyze pharmacodynamic markers including RCE1 substrate processing

How does post-translational modification affect RCE1 antibody recognition?

Post-translational modifications (PTMs) of RCE1 can significantly impact antibody recognition and experimental outcomes:

• Potential PTM sites:

  • RCE1 contains several consensus sequences for phosphorylation, glycosylation, and ubiquitination

  • The regulatory deubiquitinase USP17 has been shown to modulate RCE1 Iso2 protein levels, suggesting active ubiquitination/deubiquitination regulation

• Antibody epitope considerations:

  • Antibodies targeting regions containing PTM sites may show variable binding depending on modification status

  • Phospho-specific antibodies may be necessary to distinguish active vs. inactive forms

  • For N-terminal targeted antibodies, consider potential signal peptide cleavage effects

• Experimental approaches to address PTM interference:

  • Pretreat samples with phosphatases, deglycosylases, or deubiquitinases to normalize modification status

  • Compare detection patterns across multiple antibodies targeting different epitopes

  • Use epitope-tagged recombinant RCE1 as an alternative detection method when PTMs interfere with antibody recognition

• Validation strategies:

  • Western blotting under various conditions that alter PTM status

  • Mass spectrometry analysis to identify actual modification sites

  • Compare antibody reactivity in cellular stress conditions known to alter PTM profiles

The interaction between RCE1 and USP17 provides a particularly important consideration, as research has shown differential regulation of RCE1 isoforms that could confound experimental interpretation if not properly accounted for .

What are the experimental challenges in determining RCE1's complete substrate profile?

Identifying the complete substrate profile of RCE1 presents several distinct experimental challenges:

• Substrate characteristics and limitations:

  • RCE1 cleaves only prenylated substrates, requiring specialized techniques to maintain substrate prenylation

  • The hydrophobic nature of these substrates complicates traditional proteomic approaches

  • The enzyme preferentially recognizes substrates with specific amino acids (Ile, Leu, or Val) at the a₂ position of the CAAX motif

• Technical approaches and challenges:

  • Proteomic strategies: Requires specialized enrichment techniques for prenylated proteins

  • Comparative analyses: Comparing proteomes of wild-type vs. Rce1-deficient cells can identify differences but may miss indirect effects

  • Substrate mimetics: Can facilitate in vitro studies but may not fully recapitulate natural substrate specificity

• Experimental design strategies:

  • Develop bioorthogonal labeling methods for prenylated proteins

  • Employ chemical proteomic approaches with activity-based probes

  • Utilize targeted mass spectrometry with isotope-labeled reference peptides

  • Implement CRISPR-based screens to identify functional RCE1 substrates

• Validation requirements:

  • Biochemical confirmation of direct cleavage

  • Structural analysis of enzyme-substrate interactions

  • Functional studies demonstrating biological relevance of processing

Research has revealed that beyond Ras proteins, RCE1 processes various other substrates including G-protein γ subunits and nuclear lamins. Interestingly, RCE1 also appears to be involved in regulating bacterial effector proteins during host infection , suggesting its substrate profile extends beyond endogenous eukaryotic proteins.

How can researchers design experiments to assess off-target effects of RCE1 inhibitors?

Designing robust experiments to evaluate off-target effects of RCE1 inhibitors requires systematic approaches:

• Comprehensive selectivity profiling:

  • Test against related proteases and enzymes in biochemical assays

  • Screen against protein panels (kinases, GPCRs, ion channels) to identify unexpected interactions

  • Employ thermal shift assays to detect binding to proteins beyond known targets

• Genetic control systems:

  • Compare inhibitor effects in wild-type cells versus those with Rce1 gene deletions

  • Engineer cells expressing inhibitor-resistant RCE1 mutants to distinguish on-target from off-target effects

  • Utilize dose-response studies comparing genetic knockdown/knockout with inhibitor treatment

• Unbiased phenotypic assessments:

  • Perform global transcriptomic profiling comparing inhibitor treatment with genetic RCE1 depletion

  • Conduct broad metabolomic analyses to identify unexpected metabolic alterations

  • Use phosphoproteomic approaches to identify pathway activations/inhibitions inconsistent with pure RCE1 inhibition

• Targeted functional assays:

  • Evaluate effects on specific CAAX proteins beyond Ras (e.g., G-protein γ subunits, nuclear lamins)

  • Assess cellular processes independent of known RCE1 substrates

  • Examine tissue-specific effects that might indicate off-target toxicity

Studies with current RCE1 inhibitor candidates such as 8-hydroxyquinoline derivatives have shown promising activity in mislocalizing Ras isoforms , but comprehensive selectivity profiling remains crucial, particularly given the diverse phenotypes observed in tissue-specific Rce1 knockout models .

What methodological approaches enable studying RCE1 in infectious disease models?

RCE1's involvement in infectious disease processes offers unique research opportunities through several methodological approaches:

• Parasite systems:

  • In vitro growth inhibition assays for Plasmodium and Trypanosoma using RCE1 inhibitors

  • Comparative studies between parasite and human RCE1 to identify structural/functional differences

  • Transgenic parasite models with modified RCE1 expression/activity

  • High-throughput screening for selective inhibitors of parasite RCE1

• Bacterial pathogenesis models:

  • Assays measuring RCE1-dependent modification of bacterial effector proteins

  • Cell infection models to assess host RCE1's role in bacterial pathogenicity

  • Studies targeting prokaryotic RCE1 homologs in Staphylococcus aureus and Streptococcus pneumoniae

• Technical considerations:

  • Species-specific antibodies or epitope tagging approaches for distinguishing host from pathogen RCE1

  • Biosafety considerations when working with pathogens

  • Specialized culture systems for host-pathogen interaction studies

• Validation strategies:

  • Genetic manipulation of host and/or pathogen RCE1

  • Pharmacological inhibition studies with appropriate controls

  • In vivo infection models with tissue-specific RCE1 modulation

The dual targeting potential (host vs. pathogen RCE1) presents both opportunities and challenges. Research has shown that inhibitors preferentially targeting parasite RCE1 over human variants could have clinical value for diseases like malaria and African sleeping sickness . Additionally, prokaryotic RCE1 appears to regulate pathogenicity in certain bacteria, suggesting alternative therapeutic approaches.

How does RCE1 deficiency impact cell growth and transformation in research models?

Studies on RCE1 deficiency have revealed complex effects on cellular phenotypes with important methodological implications:

• Cell growth effects:

  • Conditional knockout studies using Rce1ᶠˡᵒˣ/ᶠˡᵒˣ cells have allowed precise assessment of RCE1's role in proliferation

  • "Competitive fitness" experiments mixing Rce1-expressing and Rce1-deficient cells have demonstrated growth disadvantages in RCE1-deficient populations

  • Effects may vary by cell type and environmental conditions, requiring careful experimental design

• Transformation and oncogenic signaling:

  • RCE1 deficiency has been shown to exacerbate K-Ras induced myeloproliferative disease in hematopoietic tissue

  • Impact on Ras-mediated transformation appears context-dependent

  • Both membrane association and signaling activities of Ras proteins are affected by RCE1 deficiency

• Tissue-specific phenotypes:

  • Cardiac tissue shows severe effects with high rates of lethal cardiomyopathy upon RCE1 loss

  • Retinal tissue exhibits compromised photoreceptor function and degeneration

  • These differential effects highlight the importance of tissue-specific experimental approaches

• Methodological considerations:

  • Acute vs. chronic RCE1 deficiency may produce different outcomes

  • Compensatory mechanisms may emerge in long-term studies

  • Combined approaches using both genetic ablation and pharmacological inhibition provide complementary insights

The complex phenotypes observed in different tissues underscore the value of conditional knockout systems for studying RCE1 function. These systems allow researchers to compare phenotypes of normal RCE1 expression and RCE1 deficiency in the same cell line, offering powerful controls for experimental studies .

What are the optimal experimental conditions for detecting RCE1 in Western blotting protocols?

Optimizing Western blotting protocols for RCE1 detection requires attention to its characteristics as a multi-span membrane protein:

• Sample preparation considerations:

  • Lysis buffers: Use buffers containing mild detergents (0.5-1% Triton X-100, NP-40, or CHAPS)

  • Membrane solubilization: Complete solubilization may require stronger ionic detergents (0.1-0.5% SDS) while maintaining protein structure

  • Denaturation temperature: Avoid boiling samples (use 37-70°C for 10-15 minutes) to prevent membrane protein aggregation

  • Reducing agents: Include 5-10 mM DTT or β-mercaptoethanol to break disulfide bonds

• Gel electrophoresis parameters:

  • Gel percentage: 10-12% polyacrylamide gels provide optimal resolution for RCE1 (30-37 kDa)

  • Running conditions: Lower voltage (80-100V) for longer duration improves resolution

  • Molecular weight markers: Include appropriate markers spanning 25-50 kDa range

• Transfer optimizations:

  • Transfer buffer: Add 10-20% methanol and 0.05-0.1% SDS to facilitate transfer of hydrophobic proteins

  • Transfer conditions: Lower amperage (250-300 mA) for longer time (2-3 hours) or overnight at 30V

  • Membrane selection: PVDF membranes typically provide better results than nitrocellulose for hydrophobic proteins

• Antibody conditions:

  • Blocking: 5% non-fat milk in TBST is typically effective; for phospho-specific detection, use 3-5% BSA

  • Primary antibody: Incubation at 4°C overnight provides optimal results with dilutions between 1:500-1:2000

  • Secondary antibody: HRP-conjugated anti-rabbit IgG at 1:5000-1:10000 dilution for 1 hour at room temperature

• Detection considerations:

  • Enhanced chemiluminescence: Standard ECL systems are usually sufficient

  • Exposure time: Multiple exposures (10 seconds to 5 minutes) to capture optimal signal

Antibodies targeting different epitopes may require specific optimization. For example, antibodies targeting the AA 155-204 region have shown reliable detection across multiple species .

How can researchers accurately localize RCE1 in relation to other cellular compartments?

Accurately determining RCE1's subcellular localization requires specialized approaches addressing its membrane protein characteristics:

• Immunofluorescence optimization:

  • Fixation: 4% paraformaldehyde (10-15 minutes) preserves membrane structure

  • Permeabilization: Graduated approach using 0.1-0.2% Triton X-100 or 0.1% saponin to access intracellular epitopes while preserving membrane integrity

  • Blocking: Extended blocking (1-2 hours) with 5-10% normal serum matching secondary antibody host

  • Antibody dilution: Typically 1:100-1:500 for primary antibodies against RCE1

• Colocalization strategies:

  • ER markers: PDI, calnexin, or KDEL-tagged proteins as established ER markers

  • Sequential staining: For same-species antibodies, use directly conjugated antibodies or sequential staining with intermediate blocking steps

  • Quantitative colocalization: Measure Pearson's or Mander's coefficients for objective assessment

• Advanced imaging techniques:

  • Super-resolution microscopy: Techniques like STORM or PALM provide nanometer-scale resolution of membrane protein localization

  • Live-cell imaging: Utilizing GFP-tagged RCE1 constructs for dynamic localization studies

  • FRET analysis: To assess proximity to interaction partners when using appropriately tagged constructs

• Complementary approaches:

  • Subcellular fractionation: Biochemical validation of imaging results through differential centrifugation

  • Electron microscopy: Immunogold labeling for ultrastructural localization

  • Proximity labeling: BioID or APEX2 approaches to identify neighboring proteins